



Universiteit
Leiden
The Netherlands

F-18-FDG PET/CT for the diagnosis of aortic inflammation in COVID-19

Bijl, P. van der; Stassen, J.; Bax, J.J.

Citation

Bijl, P. van der, Stassen, J., & Bax, J. J. (2022). F-18-FDG PET/CT for the diagnosis of aortic inflammation in COVID-19. *Journal Of Nuclear Cardiology*, 30, 83-84.
doi:10.1007/s12350-022-02950-5

Version: Publisher's Version
License: [Leiden University Non-exclusive license](#)
Downloaded from: <https://hdl.handle.net/1887/3567771>

Note: To cite this publication please use the final published version (if applicable).



^{18}F -FDG PET/CT for the diagnosis of aortic inflammation in COVID-19

Pieter van der Bijl, MD, PhD,^a Jan Stassen, MD,^a and Jeroen J. Bax, MD, PhD^{a,b}

^a Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Leiden, The Netherlands

^b Heart Center, University of Turku and Turku University Hospital, Turku, Finland

Received Feb 22, 2022; accepted Feb 22, 2022

doi:10.1007/s12350-022-02950-5

See related article, pp. 74–82

A prominent component of the pathophysiology of COVID-19, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is vascular involvement.¹ The latter includes vascular and endothelial dysfunction, as well as inflammation, i.e., vasculitis.¹ COVID-related vasculitis is challenging to diagnose clinically, necessitating the use of specific diagnostic investigations. ^{18}F -fluoro-deoxyglucose (FDG)-positron emission tomography (PET)/ computed tomography (CT) is an established technique for visualizing large-vessel inflammation.² The non-invasive diagnosis of vasculitis by imaging modalities, however, has not been explored very thoroughly in the context of the COVID-19 pandemic.

In the current issue of the journal, Vlachopoulos et al. performed ^{18}F -FDG PET/CT imaging in 20 severely and critically ill patients with COVID-19, who were admitted to hospital.³ They were compared to 10 age- and sex-matched individuals with malignancies who were in remission and served as the control group.³ PET/CT scans were performed at a median of 60 (IQR 45–74) days after the diagnosis, and no difference in aortic target-to-background ratio (TBR) was found between the patient and control groups ($P = 0.422$).³ In contrast, index TBR (region with the highest TBR)

differed between patients and controls, in the group where scans were performed before or at 60 days after the diagnosis ($P = 0.036$). A fair correlation was identified between TBR and serum C-reactive protein (CRP) levels ($P = 0.004$), and arterial TBR was independently associated with the time from diagnosis.³ The results therefore suggest that ^{18}F -FDG PET/CT can be used to diagnose and monitor large-vessel involvement in COVID-19, and that it resolves over time.

Endothelial dysfunction, including vasculitis (characterized by lymphocyte infiltration) and intravascular thrombosis, has been well documented in COVID-19. Vascular dysfunction may lead to serious complications, e.g., arterial and venous thromboses, as well as coronary and aortic dissection.¹ Large-vessel inflammation can be visualized with ^{18}F -FDG PET/CT, since inflammatory cells overexpress glucose transporters which avidly take up glucose and ^{18}F -FDG.² While alternative techniques are available for the diagnosis of large-vessel vasculitis, e.g., biopsy, invasive angiography, ultrasound, and magnetic resonance (MR) imaging, these are impractical (e.g., biopsy), demonstrate changes only in advanced or late-stage disease (e.g., invasive angiography), and can be non-specific (e.g., ultrasound).² ^{18}F -FDG PET/CT, on the other hand, has a high sensitivity and specificity for the diagnosis of large-vessel vasculitis.⁴ The uptake of ^{18}F -FDG into large blood vessels was correlated with acute phase reactants in a study including 26 patients with giant cell or Takayasu's arteritis—similar to the current study—suggesting that ^{18}F -FDG PET/CT is a sensitive technique for detecting early disease in conditions causing inflammation of large vessels.^{2,3} The presence of inflammation in large vessels has recently been demonstrated in a study of 10 patients who had recovered from acute COVID-19, but who were suffering from persistent symptoms, i.e., ‘‘long COVID.’’⁵ The current study, however, is the first to investigate the

Reprint requests: Pieter van der Bijl, MD, PhD, Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands; pieter.vanderbijl@gmail.com

J Nucl Cardiol 2023;30:83–4.

1071-3581/\$34.00

Copyright © 2022 The Author(s) under exclusive licence to American Society of Nuclear Cardiology

relation of large-vessel inflammation, diagnosed with ¹⁸F-FDG PET/CT, with the time from diagnosis.³

Early identification of the degree of vascular inflammation in COVID-19 patients might be useful in planning management. Strategies for suppression of large-vessel vasculitis in COVID-19 still have to be defined, although the use of systemic glucocorticoids appears logical, based on the beneficial effect in large-vessel vasculitides in general, as well as serious manifestations of COVID-19.^{6,7} Although the outcome implications (including the impact of the severity and duration of vascular inflammation) of large-vessel vasculitis due to COVID-19 are still unclear, the clinical use of ¹⁸F-FDG PET/CT is promising, and the technique has been demonstrated to predict relapses in large-vessel vasculitides which were clinically in remission.⁸ A confounder regarding the use of ¹⁸F-FDG PET/CT to detect large-vessel vasculitis is the accumulation of ¹⁸F-FDG in atherosclerotic plaques. This occurs in about 50% of all PET scans, although it can potentially be distinguished from vasculitis by the lower grade of uptake.^{2,9} Infection control protocols are also required for the performance of PET/CT scans in patients with COVID-19, which may limit its use in daily practice. An additional consideration is the fact that PET/CT involves radiation, especially when repeat scans may be required for monitoring the degree of vascular inflammation. PET/MR and novel MR contrast agents (e.g., ultrasmall superparamagnetic iron oxide) are promising alternatives for the diagnosis and prognostication of large-vessel vasculitis without the use of radiation, but their application has not been investigated in the context of COVID-19.¹⁰

Disclosures

The Department of Cardiology of Leiden University Medical Center received research grants from Abbott Vascular, Bayer, Biotronik, Bioventrix, Boston Scientific, Edwards Lifesciences, GE Healthcare and Medtronic. J.B. received speaker fees from Abbott Vascular. P.V.D.B. and J.S. have nothing to disclose.

References

1. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *N Engl J Med* 2020;383:120-8. <https://doi.org/10.1056/NEJMoa2015432>.
2. Walter MA, Melzer RA, Schindler C, Muller-Brand J, Tyndall A, Nitzsche EU. The value of [¹⁸F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. *Eur J Nucl Med Mol Imaging* 2005;32:674-81. <https://doi.org/10.1007/s00259-004-1757-9>.
3. Vlachopoulos C, Terentes-Printzios D, Katsaounou P, Solomou E, Gardikioti V, Exarchos D, et al. Time-related aortic inflammatory response, as assessed with ¹⁸F-FDG PET/CT, in patients hospitalized with severe or critical COVID-19: The COVAIR study. *J Nucl Cardiol* 2022.
4. Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, Fain O, et al. Management of large-vessel vasculitis with FDG-PET: A systematic literature review and meta-analysis. *Medicine* 2015;94:e622. <https://doi.org/10.1097/MD.0000000000000622>.
5. Sollini M, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Gelardi F, et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: An [(¹⁸F)FDG-PET/CT study. *Eur J Nucl Med Mol Imaging* 2021;48:1460-6. <https://doi.org/10.1007/s00259-020-05084-3>.
6. Hellmich B, Agueda A, Monti S, Buttgerit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis* 2020;79:19-30. <https://doi.org/10.1136/annrheumdis-2019-215672>.
7. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med* 2021;384:693-704. <https://doi.org/10.1056/NEJMoa2021436>.
8. Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, et al. (¹⁸F)F-Fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. *Arthritis Rheumatol* 2018;70:439-49. <https://doi.org/10.1002/art.40379>.
9. Yun M, Jang S, Cucchiara A, Newberg AB, Alavi A. ¹⁸F FDG uptake in the large arteries: A correlation study with the atherogenic risk factors. *Semin Nucl Med* 2002;32:70-6. <https://doi.org/10.1053/snuc.2002.29279>.
10. Einspieler I, Thurmel K, Pyka T, Eiber M, Wolfram S, Moog P, et al. Imaging large vessel vasculitis with fully integrated PET/MRI: A pilot study. *Eur J Nucl Med Mol Imaging* 2015;42:1012-24. <https://doi.org/10.1007/s00259-015-3007-8>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.